{"id":33677,"date":"2025-05-19T17:34:53","date_gmt":"2025-05-19T09:34:53","guid":{"rendered":"https:\/\/flcube.com\/?p=33677"},"modified":"2025-05-19T17:34:54","modified_gmt":"2025-05-19T09:34:54","slug":"suzhous-pegbio-launches-hong-kong-ipo-amid-pipeline-progress","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33677","title":{"rendered":"Suzhou&#8217;s PegBio Launches Hong Kong IPO Amid Pipeline Progress"},"content":{"rendered":"\n<p>Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO, offering 19.28 million shares at HKD 15.6 (USD 2.0) per share, raising total proceeds of USD 38 million. This milestone event underscores the company&#8217;s commitment to advancing therapies for chronic diseases.<\/p>\n\n\n\n<p><strong>Company Overview and Pipeline<\/strong><br>Founded in 2008, PegBio is dedicated to the discovery and development of peptides and small molecule drugs for chronic conditions, with a focus on metabolic disorders. The company&#8217;s robust pipeline includes one core product and five other candidate drugs, targeting indications such as type 2 diabetes (T2DM), obesity, nonalcoholic steatohepatitis (NASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia.<\/p>\n\n\n\n<p><strong>Core Product PB-119<\/strong><br>PegBio&#8217;s core product, PB-119, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed in-house. The New Drug Application (NDA) for PB-119 in the treatment of T2DM was accepted for review in China in September of the previous year. This weekly injectable therapy offers multiple benefits, including blood sugar control, weight loss, and improved cardiovascular markers, with a favorable safety profile and high patient compliance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025051900014_c-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025051900014_c (1).\"><\/object><a id=\"wp-block-file--media-f7089207-c599-4c46-940d-f6826c29f13e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025051900014_c-1.pdf\">2025051900014_c (1)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025051900014_c-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f7089207-c599-4c46-940d-f6826c29f13e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33679,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[69,39,4078,72,76,86,2105],"class_list":["post-33677","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cvd","tag-diabetes","tag-hkg-2565","tag-ipo","tag-nash","tag-obesity","tag-pegbio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Suzhou&#039;s PegBio Launches Hong Kong IPO Amid Pipeline Progress - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO, offering 19.28 million shares at HKD 15.6 (USD 2.0) per share, raising total proceeds of USD 38 million. This milestone event underscores the company&#039;s commitment to advancing therapies for chronic diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33677\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou&#039;s PegBio Launches Hong Kong IPO Amid Pipeline Progress\" \/>\n<meta property=\"og:description\" content=\"Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO, offering 19.28 million shares at HKD 15.6 (USD 2.0) per share, raising total proceeds of USD 38 million. This milestone event underscores the company&#039;s commitment to advancing therapies for chronic diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33677\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-19T09:34:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-19T09:34:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1905.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou&#8217;s PegBio Launches Hong Kong IPO Amid Pipeline Progress\",\"datePublished\":\"2025-05-19T09:34:53+00:00\",\"dateModified\":\"2025-05-19T09:34:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677\"},\"wordCount\":188,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1905.webp\",\"keywords\":[\"CVD\",\"Diabetes\",\"HKG: 2565\",\"IPO\",\"NASH\",\"Obesity\",\"PegBio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33677#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33677\",\"name\":\"Suzhou's PegBio Launches Hong Kong IPO Amid Pipeline Progress - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1905.webp\",\"datePublished\":\"2025-05-19T09:34:53+00:00\",\"dateModified\":\"2025-05-19T09:34:54+00:00\",\"description\":\"Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO, offering 19.28 million shares at HKD 15.6 (USD 2.0) per share, raising total proceeds of USD 38 million. This milestone event underscores the company's commitment to advancing therapies for chronic diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33677\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1905.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1905.webp\",\"width\":1080,\"height\":608,\"caption\":\"Suzhou's PegBio Launches Hong Kong IPO Amid Pipeline Progress\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33677#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou&#8217;s PegBio Launches Hong Kong IPO Amid Pipeline Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou's PegBio Launches Hong Kong IPO Amid Pipeline Progress - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO, offering 19.28 million shares at HKD 15.6 (USD 2.0) per share, raising total proceeds of USD 38 million. This milestone event underscores the company's commitment to advancing therapies for chronic diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33677","og_locale":"en_US","og_type":"article","og_title":"Suzhou's PegBio Launches Hong Kong IPO Amid Pipeline Progress","og_description":"Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO, offering 19.28 million shares at HKD 15.6 (USD 2.0) per share, raising total proceeds of USD 38 million. This milestone event underscores the company's commitment to advancing therapies for chronic diseases.","og_url":"https:\/\/flcube.com\/?p=33677","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-19T09:34:53+00:00","article_modified_time":"2025-05-19T09:34:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1905.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33677#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33677"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou&#8217;s PegBio Launches Hong Kong IPO Amid Pipeline Progress","datePublished":"2025-05-19T09:34:53+00:00","dateModified":"2025-05-19T09:34:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33677"},"wordCount":188,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33677#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1905.webp","keywords":["CVD","Diabetes","HKG: 2565","IPO","NASH","Obesity","PegBio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33677#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33677","url":"https:\/\/flcube.com\/?p=33677","name":"Suzhou's PegBio Launches Hong Kong IPO Amid Pipeline Progress - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33677#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33677#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1905.webp","datePublished":"2025-05-19T09:34:53+00:00","dateModified":"2025-05-19T09:34:54+00:00","description":"Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO, offering 19.28 million shares at HKD 15.6 (USD 2.0) per share, raising total proceeds of USD 38 million. This milestone event underscores the company's commitment to advancing therapies for chronic diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33677#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33677"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33677#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1905.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1905.webp","width":1080,"height":608,"caption":"Suzhou's PegBio Launches Hong Kong IPO Amid Pipeline Progress"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33677#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou&#8217;s PegBio Launches Hong Kong IPO Amid Pipeline Progress"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1905.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33677"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33677\/revisions"}],"predecessor-version":[{"id":33680,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33677\/revisions\/33680"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33679"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}